Nuformix plc
Nuformix plc

Nuformix plc share price, company news, analysis and interviews

Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing

The company uses their expertise in discovering, developing and patenting novel drug forms with improved physical properties, to develop new products in new indications that are differentiated from the original by way of: dosage, delivery route or presentation, thus creating new and attractive commercial opportunities.

Nuformix plc

Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities:

NXP001 (aprepitant) – oncology – Phase 1 ready

NXP001 is our new form of the drug aprepitant that is currently marketed as a product in the oncology supportive care setting

  • Aprepitant has a number of known properties, notably the NK-1 receptor that is involved in cellular responses.
  • Literature data suggests that aprepitant could have benefits in oncology, i.e., beyond the currently marketed indications. For example, it has shown antiproliferative properties in tumoral cell lines of glioma, neuroblastoma, retinoblastoma, pancreas, larynx, colon, and gastric carcinoma1

 

Licensing agreement

On 10 September 2021, Nuformix signed an exclusive global licensing agreement with Oxilio Ltd (“Oxilio”), a privately held pharmaceutical development company, for NXP001 (a proprietary new form of aprepitant) for oncology indications.

Under the terms of the licensing agreement, Oxilio has obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments and a royalty on net sales, capped at £2 million per annum.

Nuformix plc

NXP002 (inhaled tranilast) for IPF -preclinical

NXP002 is Nuformix’s lead asset and a potential novel inhaled treatment for idiopathic pulmonary fibrosis

  • Repurposed new form of the drug tranilast, to be delivered in an inhaled formulation.
  • Tranilast has a long history of safe use as an oral drug for allergies but there is evidence (widely published in peer reviewed scientific papers) that supports its potential in fibrosis, including IPF.
  • Overall findings suggest that tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2-mediated extra-cellular matrix (ECM) protein  production, a major therapeutic target in IPF, presenting it as a promising and novel anti-fibrotic agent. 1
  • NXP002 is differentiated as it is a new form of tranilast and will be formulated for delivery direct to the lungs by inhalation, a new route of administration for this drug.
  • Delivery by the inhalation route is a well-known strategy for treatment of lung diseases to yield greater efficacy and reduce systemic side-effects compared to oral treatment.
  • We have filed two patent applications on new forms of tranilast, one of which is granted and the other is issued in the US and undergoing examination in other territories.
  • Our studies have yielded positive data underpinning the potential of NXP002 as an IPF treatment, including potential for use in combination with standard of care therapy and support continuing to develop this asset.
  • Our studies have yielded positive data underpinning the potential of NXP002 as an IPF treatment, including potential for use in combination with standard of care therapy and support continuing to develop this asset.
    • The first of these studies demonstrated that NXP002 can be efficiently delivered to the lung, achieving significant drug levels, whilst limiting systemic exposure compared to oral dosing
    • The second in vivo study evaluated the pharmacodynamics of NXP002 when delivered by nebulisation. This study showed that inhaled NXP002 could dose-dependently regulate the production of fibrosis-relevant mediators

The final planned study as part of the NXP002 pre-clinical data package is an in vivo study investigating the durability of the pharmacodynamic effect. The Company anticipates receiving the data for this study in early 2022 prior to seeking licensing/partnering opportunities.

Nuformix plc

Nuformix plc 5 day trade history

Share this page

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Nuformix plc

Nuformix plc share price

Fundamentals

52 Week High / Low

Analyst Notes & Comments

Questions & Answers

More Information

Latest Nuformix plc News

Interviews

Questions & Answers

Broker Notes & Comments

Nuformix plc share price

Fundamentals

Share this page

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.